Aller au contenu principal
Accès ouvert déclaré 2025 article

Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis

3Citations signalées, ce qui n’est pas une note de qualité
4Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

OBJECTIVE: Gastrointestinal adverse effects are the most commonly reported adverse effects associated with the use of antidepressants. While existing studies on the gastrointestinal effects of antidepressant medications offer valuable insights, there are still opportunities to enhance the evidence base. METHODS: We included double-blind randomized controlled trials of major depressive disorder (MDD). Eligible studies must focus on comparing the use of 21 commonly used antidepressants in patients with MDD and reporting data on treatment-emergent gastrointestinal SEs. We selected 196 studies that reported specific numbers of individuals with gastrointestinal adverse effects, involving a total of 57,162 patients. A network and dose‒response meta-analysis was conducted. RESULTS: Compared with placebo, 16 antidepressants had higher odds ratios (ORs) for nausea and vomiting, 15 antidepressants had higher ORs for constipation, 8 antidepressants had higher ORs for diarrhoea, 8 antidepressants had higher ORs for anorexia, 12 antidepressants had higher ORs for dry mouth, and 3 antidepressants had higher ORs for dyspepsia. CONCLUSIONS: Commonly used antidepressants have different gastrointestinal effects. Duloxetine, levomilnacipran, and vilazodone carry a higher risk of inducing nausea and vomiting, whereas trazodone, amitriptyline, agomelatine, and mirtazapine tend to be better tolerated. Amitriptyline, clomipramine, and reboxetine are more prone to induce constipation. Diarrhoea is more commonly associated with vilazodone, fluvoxamine, and sertraline. Amitriptyline, reboxetine, and duloxetine are more likely to cause anorexia. Amitriptyline, reboxetine, and trazodone are related to causing dry mouth. Compared with the placebo, amitriptyline, fluoxetine, and paroxetine were associated with a greater incidence of dyspepsia.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis
Date Crossref
25/11/2025
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Treatment of Major DepressionGastrointestinal motility and disordersTryptophan and brain disorders

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.